Next Article in Journal
Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
Next Article in Special Issue
Glucosamine Enhances TRAIL-Induced Apoptosis in the Prostate Cancer Cell Line DU145
Previous Article in Journal
In Vitro Anti-Inflammatory and Immunomodulatory Activities of an Extract from the Roots of Bupleurum rotundifolium
Previous Article in Special Issue
Early Stage Glycosylation Biomarkers in Alzheimer’s Disease
Communication

Targeting Aberrant Sialylation to Treat Cancer

Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK
*
Author to whom correspondence should be addressed.
Received: 20 September 2019 / Accepted: 10 October 2019 / Published: 13 October 2019
(This article belongs to the Special Issue Application of Glycobiology in the Treatment of Diseases)
Cell surface carbohydrates (known as glycans) are often aberrantly expressed or found at atypical levels in cancer. Glycans can impact all steps in tumour progression, from malignant transformation to metastasis, and have roles in all the cancer hallmarks. An increased understanding of glycans in the metastatic cascade offers exciting new therapeutic opportunities. Glycan-based targeting strategies are currently being tested in clinical trials and are a rich and untapped frontier for development. As we learn more about cancer glycobiology, new targets will continue to emerge for drug design. One key change in tumour glycosylation is the upregulation of cancer-associated sialylated glycans. Abnormal sialylation is integral to tumour growth, metastasis and immune evasion; therefore, targeting sialic acid moieties in cancer could be of high therapeutic value. Here, we summarise the changes to sialic acid biology in cancer and discuss recent advances and technologies bringing sialic-acid targeting treatments to the forefront of cancer therapeutics. View Full-Text
Keywords: glycosylation; glycans; cancer; sialic acid; sialylation; immunotherapy; therapeutics glycosylation; glycans; cancer; sialic acid; sialylation; immunotherapy; therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Munkley, J.; Scott, E. Targeting Aberrant Sialylation to Treat Cancer. Medicines 2019, 6, 102. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines6040102

AMA Style

Munkley J, Scott E. Targeting Aberrant Sialylation to Treat Cancer. Medicines. 2019; 6(4):102. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines6040102

Chicago/Turabian Style

Munkley, Jennifer, and Emma Scott. 2019. "Targeting Aberrant Sialylation to Treat Cancer" Medicines 6, no. 4: 102. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines6040102

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop